Summary
The E-cadherin–catenin complex plays an important role in establishing and maintaining intercellular connections and morphogenesis and reduced expression of its constituent molecules is associated with invasion and metastasis. In the present study, we examined E-cadherin and α-, β- and γ-catenin levels in tumour tissues obtained by radical prostatectomy in order to investigate the relationship with histopathological tumour invasion. Immunohistochemical findings for 45 prostate cancer specimens demonstrated aberrant expression of each molecule to be associated with dedifferentiation and, in addition, alteration of staining patterns for the three types of catenin was significantly correlated with capsular but not lymphatic or vascular invasion. The data thus suggest that three types of catenin may be useful predictive markers for biological aggressiveness of prostate cancer.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Behrens, J., Mareel, M. M., Van Roy, F. M. & Birchmeier, W. (1989). Dissecting tumor cell invasion: epithelial cells acquire invasive properties after the loss of uvomorulin-mediated cell–cell adhesion. J Cell Biol 108: 2435–2447.
Black, R. J., Bray, F., Ferlay, J. & Parkin, D. M. (1997). Cancer incidence and mortality in the European Union: cancer registry data and estimates of national incidence for 1990. Eur J Cancer 33: 1075–1107.
Boring, C. C., Squires, T. S. & Tong, T. (1993). Cancer statistics, 1993. CA Cancer J Clin 43: 7–26.
Bussemakers, M. J. G., Van Moorselaar, R. J. A., Giroldi, L. A., Ichikawa, T., Issacs, J. T., Takeichi, M., Debruyne, F. M. J. & Schalken, J. A. (1992). Decreased expression of E-cadherin in the progression of rat prostatic cancer. Cancer Res 52: 2916–2922.
Carter, H. B. & Coffey, D. S. (1989). Prediction of tumor behavior in prostate cancer. In The Second Tokyo Symposium. Karr JP, Yamanaka H (eds), pp. 19–27. Elsevier: New York
Fournier, G., Latil, A., Amet, Y., Abalain, J. H., Volant, A., Mangin, P., Floch, H. H. & Lidereau, R. (1995). Gene amplifications in advanced-stage human prostate cancer. Urol Res 22: 343–347.
Gleason, D. F. (1977). Histological grading and clinical staging of prostatic carcinoma: urologic pathology. In The Prostate, Tannenbaum M (ed), pp 171–197. Lea and Fabiger: Philadelphia
Grayhack, J. T. & Assimos, D. G. (1983). Prognostic significance of tumor grade and stage in the patient with carcinoma of the prostate. Prostate 4: 13–31.
Hall, R. R. (1996). Screening and early detection of prostate cancer will decrease morbidity and mortality from prostate cancer: the argument against. Eur Urol Suppl 2: 24–26.
Hinck, L., Näthke, I. S., Papkoff, J. & Nelson, W. J. (1994). Dynamics of cadherin/catenin complex formation: novel protein interactions and pathways of complex assembly. J Cell Biol 125: 1327–1340.
Jawhari, A., Jordan, S., Poole, S., Browne, P., Pignatelli, M. & Farthing, M. J. G. (1997). Abnormal immunoreactivity of the E-cadherin-catenin complex in gastric carcinoma: relationship with patient survival. Gastroenterology 112: 46–54.
Kadowaki, T., Shiozaki, H., Inoue, M., Tamura, S., Oka, H., Doki, Y., Iihara, K., Matsui, S., Iwazawa, T., Nagafuchi, A., Tsukita, S. & Mori, T. (1994). E-cadherin and α-catenin expression in human esophageal cancer. Cancer Res 54: 291–296.
Korinek, V., Barker, N., Morin, P. J., van Wichen, D., de Weger, R., Kinzler, K. W., Vogelstein, B. & Clevers, H. (1997). Constitutive transcriptional activation by a β-catenin-Tcf complex in APC−/− colon carcinoma. Science (Washington DC) 275: 1784–1787.
Kowalczyk, A. P., Palka, H. L., Luu, H. H., Nilles, L. A., Anderson, J. E., Wheelock, M. J. & Green, K. J. (1994). Posttranslational regulation of plakoglobin expression. J Biol Chem 269: 31214–31223.
Matsui, S., Shiozaki, H., Inoue, M., Tamura, S., Doki, Y., Kadowaki, T., Iwazawa, T., Shimaya, K., Nagafuchi, A., Tsukita, S. & Mori, T. (1994). Immunohistochemical evaluation of alpha-catenin expression in human gastric cancer. Virch Arch A 424: 375–381.
Morin, P. J., Sparks, A. B., Korinek, V., Barker, N., Clevers, H., Vogelstein, B. & Kinzler, K. W. (1997). Activation of β-catenin-Tcf signaling in colon cancer by mutations in β-catenin or APC. Science (Washington DC) 275: 1787–1790.
Nagafuchi, A., Takeichi, M. & Tsukita, S. (1991). The 102 kd cadherin-associated protein: similarity to vinculin and posttranscriptional regulation of expression. Cell 65: 849–857.
Nakamura, Y. (1997). Cleaning up on β-catenin. Nature Med 3: 499–500.
Ochiai, A., Akimoto, S., Shimoyama, Y., Nagafuchi, A., Tsukita, S. & Hirohashi, S. (1994). Frequent loss of α catenin expression in scirrhous carcinomas with scattered cell growth. Jpn J Cancer Res 85: 266–273.
Ozawa, M., Baribault, H. & Kemler, R. (1989). The cytoplasmic domain of the cell adhesion molecule uvomorulin associates with three independent proteins structurally related in different species. EMBO J 8: 1711–1717.
Pierceall, W. E., Woodard, A. S., Morrow, J. S., Rimm, D. & Fearon, E. R. (1995). Frequent alterations in E-cadherin and α- and β-catenin expression in human breast cancer cell lines. Oncogene 11: 1319–1326.
Pisters, L. L., Troncoso, P., Zhau, H. E., Li, W., Eschenbach, A. C. & Chung, L. W. K. (1995). C-met proto-oncogene expression in benign and malignant human prostate tissues. J Urol 154: 293–298.
Richmond, P. J. M., Karayiannakis, A. J., Nagafuchi, A., Kaisary, A. V. & Pignatelli, M. (1977). Aberrant E-cadherin and α-catenin expression in prostate cancer: correlation with patient survival. Cancer Res 57: 3189–3193.
Rimm, D. L., Sinard, J. H. & Morrow, J. S. (1995). Reduced α-catenin and E-cadherin expression in breast cancer. Lab Invest 72: 506–512.
Shibata, T., Ochiai, A., Kanai, Y., Akimoto, S., Gotoh, M., Yasui, N., Machinami, R. & Hirohashi, S. (1996). Dominant negative inhibition of the association between β-catenin and c-erbB-2 by N-terminally deleted β-catenin suppresses the invasion and metastasis of cancer cells. Oncogene 13: 883–889.
Shimazui, T., Schalken, J. A., Giroldi, L. A., Jansen, C. F. J., Akaza, H., Kenkichi, K., Debruyne, F. M. J. & Bringuier, P. P. (1996). Prognostic value of cadherin-associated molecules (α-, β-, and γ-catenins and p120cas) in bladder tumors. Cancer Res 56: 4154–4158.
Siitonen, S. M., Kononen, J. T., Helin, H. J., Rantala, I. S., Holli, K. A. & Isola, J. J. (1996). Reduced E-cadherin expression is associated with invasiveness and unfavorable prognosis in breast cancer. Am J Clin Pathol 105: 394–402.
Smart, C. R. (1997). The results of prostate carcinoma screening in the U.S. as reflected in the surveillance, epidemiology, and end results program. Cancer 80: 1835–1844.
Syrigos, K. N., Krausz, T., Waxman, J., Pandha, H., Rowlinson-Busza, G., Verne, J., Epenetos, A. A. & Pignatelli, M. (1995). E-cadherin expression in bladder cancer using formalin-fixed, paraffin-embedded tissues: correlation with histopathological grade, tumor stage and survival. Int J Cancer 64: 367–370.
Takeichi, M. (1991). Cadherin cell adhesion receptors as a morphogenetic regulator. Science (Washington DC) 251: 1451–1455.
Tominaga, S. & Kuroishi, T. (1997). An ecological study on diet/nutrition and cancer in Japan. Int J Cancer Suppl 10: 2–6.
Umbas, R., Issacs, W. B., Bringuier, P. P., Schaafsma, H. E., Karthaus, H. F. M., Oosterhof, G. O. N., Debruyne, F. M. J. & Schalken, J. A. (1994). Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res 54: 3929–3933.
Umbas, R., Issacs, W. B., Bringuier, P. P., Xue, Y., Debruyne, F. M. J. & Schalken, J. A. (1997). Relation between aberrant α-catenin expression and loss of E-cadherin function in prostate cancer. Int J Cancer 74: 374–377.
Vleminckx, K., Vakaet, L. Jr, Mareel, M., Fiers, W. & Van Roy, F. (1991). Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell 66: 107–119.
Wasielewski, R., Rhein, A., Werner, M., Scheumann, G. F. W., Dralle, H., Pötter, E., Brabant, G. & Georgii, A. (1997). Immunohistochemical detection of E-cadherin in differentiated thyroid carcinomas correlates with clinical outcome. Cancer Res 57: 2501–2507.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Morita, N., Uemura, H., Tsumatani, K. et al. E-cadherin and α-, β- and γ-catenin expression in prostate cancers: correlation with tumour invasion. Br J Cancer 79, 1879–1883 (1999). https://doi.org/10.1038/sj.bjc.6690299
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690299
Keywords
This article is cited by
-
Molecular mechanisms of metastasis in prostate cancer
Asian Journal of Andrology (2009)
-
Decreased adhesiveness, resistance to anoikis and suppression of GRP94 are integral to the survival of circulating tumor cells in prostate cancer
Clinical & Experimental Metastasis (2008)
-
The Prognostic Significance of E-Cadherin and Liver Intestine-Cadherin Expression in Colorectal Cancer
Diseases of the Colon & Rectum (2007)
-
Restoration of plakoglobin expression in bladder carcinoma cell lines suppresses cell migration and tumorigenic potential
British Journal of Cancer (2005)
-
Luteinising hormone-releasing hormone analogue reverses the cell adhesion profile of EGFR overexpressing DU-145 human prostate carcinoma subline
British Journal of Cancer (2005)